Abstract
Rationale
Phosphodiesterase-4 (PDE4) has two conformation states based on rolipram binding, the high-affinity rolipram binding state (HARBS) and the low-affinity rolipram binding state (LARBS); their functions remain to be fully explained.
Objective
Experiments were carried out to determine the roles of the HARBS and LARBS in the mediation of antidepressant-like effects on behavior.
Materials and methods
Two animal models sensitive to antidepressant drugs, the forced-swim test (FST), and the differential-reinforcement-of-low-rate (DRL) 72-s operant schedule, were used to examine the antidepressant-like effects of rolipram, CDP840, and piclamilast, PDE4 inhibitors that interact differentially with the HARBS and LARBS, and MEM1018 and MEM1091, two novel PDE4 inhibitors. Drug discrimination vs rolipram and rolipram competition binding assays also were carried out.
Results
In the FST, rolipram and piclamilast, both at 0.1 mg/kg, produced an antidepressant-like effect, i.e., reduced immobility and increased swimming, whereas, 1 mg/kg of CDP840 or 0.5 mg/kg of MEM1018 or MEM1091 was required to produce a similar effect. Consistent with this, only rolipram and piclamilast produced antidepressant-like effects in rats under the DRL schedule of reinforcement, as evidenced by decreased response rates and increased reinforcement rates. In addition, in rats trained to discriminate rolipram from its vehicle, only rolipram and piclamilast substituted. Finally, [3H]rolipram and [3H]piclamilast binding analysis revealed that CDP840 and the two novel PDE4 inhibitors MEM1018 and MEM1091 exhibited a lower affinity for the HARBS than did rolipram.
Conclusion
These results suggest that the HARBS of PDE4 is the primary conformation important for antidepressant-like effects on behavior.
Similar content being viewed by others
References
Asanuma M, Nishibayashi S, Iwata E, Kondo Y, Nakanishi T, Vargas MG, Ogawa N (1996) Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor. Brain Res Mol Brain Res 41:210–215
Brucato FH, Hopper AT, Cook KQ, Chanas B, Deng CJ, Fiorino DF (2005) PDE4 inhibitor affinity at the high affinity rolipram binding site (HARBS) predicts efficacy in the rat pup ultrasonic vocalization model. Program No. 1024.12. Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, District of Columbia
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493–5496
Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM, Gristwood RW, Hellewell PG (1999) A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol 126:1863–1871
Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, Watson JW (1996) Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120–125
Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1–18
Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891–899
Kaulen P, Bruning G, Schneider HH, Sarter M, Baumgarten HG (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 503:229–245
Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ (2001) Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization. Drug Metab Dispos 29:232–241
Makhay MM, Houslay MD, O’Donnell JM (2001) Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Psychopharmacology (Berl) 158:297–304
Nakamura K, Ikoma Y, Kimura K, Nakada Y, Kobayashi S, Yamaguchi M, Nakagawa H (1989) Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants. Nippon Yakurigaku Zasshi 94:81–89
O’Donnell JM (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 264:1168–1178
O’Donnell JM, Frith S (1999) Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 63:185–192
O’Donnell JM, Zhang HT (2004) Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 25:158–163
O’Donnell JM, Wolfe BB, Frazer A (1984) Agonist interactions with beta adrenergic receptors in rat brain. J Pharmacol Exp Ther 228:640–647
Ortmann R, Meisburger JG (1986) Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats. Psychopharmacology (Berl) 89:273–277
Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999) Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147:162–167
Renau TE (2004) The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Curr Opin Investig Drugs 5:34–39
Reneric JP, Lucki I (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 136:190–197
Schmiechen R, Schneider HH, Wachtel H (1990) Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacol Ser (Berl) 102:17–20
Schneider HH, Schmiechen R, Brezinski M, Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105–115
Soto FJ, Hanania NA (2005) Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 11:129–134
Souness JE, Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227–236
Souness JE, Houghton C, Sardar N, Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br J Pharmacol 121:743–750
Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O’Donnell JM (2000) Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23:198–204
Zhang HT, Frith SA, Wilkins J, O’Donnell JM (2001) Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology (Berl) 159:89–97
Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O’Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587–595
Zhang HT, Huang Y, O’Donnell JM (2003) Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats. Psychopharmacology (Berl) 170:102–107
Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O’Donnell JM (2004) Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by Infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29:1432–1439
Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, O’Donnell JM (2005a) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl) 179:613–619
Zhang HT, Huang Y, Mishler K, Roerig SC, O’Donnell JM (2005b) Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats. Psychopharmacology (Berl) 182:104–115
Zhao Y, Zhang HT, O’Donnell JM (2003a) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther 305:565–572
Zhao Y, Zhang HT, O’Donnell JM (2003b) Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. J Pharmacol Exp Ther 307:246–253
Acknowledgements
This work was supported by Memory Pharmaceuticals and research grants from the National Institute of Mental Health. We thank Ajay K. Venkatesan and Sharita Woolfork for their assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, HT., Zhao, Y., Huang, Y. et al. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Psychopharmacology 186, 209–217 (2006). https://doi.org/10.1007/s00213-006-0369-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0369-4